

Attention Deficit Hyperactivity Market by Drug Type (Stimulant and Non-stimulant), Demographic (Adult and Children), Distribution Channel (Retail Pharmacy and Hospital Pharmacy), and Geography – Global Forecast up to 2026

<https://marketpublishers.com/r/ABC888B902BFEN.html>

Date: July 2021

Pages: 120

Price: US\$ 4,000.00 (Single User License)

ID: ABC888B902BFEN

Abstracts

The Attention Deficit Hyperactivity Market is projected to grow at the rate of 8.4% CAGR by 2026. Attention deficit hyperactivity disorder is considered as a mental illness previously known as attention deficit disorder. It generally affects children and also adults in few cases. Attention deficit hyperactivity disorder is a condition where the patient has difficulty sitting still, performing or concentrating on tasks, and paying attention. The patient with this disorder behaves without thinking. This disease can be diagnosed between the age of 6 and 12 years. The key fueling factor of the attention deficit hyperactivity market is the growing number of early births of babies. Research by the University of Maryland Medical Center (UMMC) indicated that 20% of preterm babies have this disorder in the present day. The rising trend of consuming toxins such as alcohol, cigarette, and drugs in pregnant women would result in children with attention deficit hyperactivity disorder. The alternative therapies such as vitamins, special diets, minerals, and herbs may hinder the attention deficit hyperactivity disorder market during growth over the forecast period.

The Attention Deficit Hyperactivity Market is has been segmented on the basis of:

Attention Deficit Hyperactivity Market based on Drug Type

Stimulant

Non-stimulant

Attention Deficit Hyperactivity Market based on Demographic

Adult (Aged 18 and above)

Children

Attention Deficit Hyperactivity Market based on Distribution Channel

Retail Pharmacy

Hospital Pharmacy

Attention Deficit Hyperactivity Market based on Geography

North America

Europe

Asia Pacific

Rest of the World

The attention deficit hyperactivity market is bifurcated into stimulant and non-stimulant based on drug type. The stimulant drug type has a significant share in the attention deficit hyperactivity market. The major share is due to the huge demand for these drugs due to their effectiveness in treating attention deficit hyperactivity disorder symptoms. Ongoing clinical trials and government provision for the use of stimulants to treat mental health disorders are other factors driving the segment's growth.

As per the demography, the attention deficit hyperactivity market is divided into adults and children. The adult segment is accounted for a substantial share in the market. This is due to the huge patient population, and it is considered that most of the adult population in the United States are affected by attention deficit hyperactivity.

According to the distribution channel, the channels are categorized into a retail pharmacy and a hospital pharmacy. Compared to hospital pharmacies, the retail pharmacy holds the maximum share in the market due to the rising number of prescriptions, increased inpatient care initiatives by retail pharmacies, and most patients prefer purchasing drugs from retail pharmacies.

In terms of geographic segment, the North American region holds a major position in the market share. The factors such as the presence of key players in the region and the rising number of collaborations are increasing market penetration. Moreover, the increase in product launches also enhances the market's growth in the region.

In addition, the increasing awareness among people worldwide about maintaining mental health is one of the key factors driving the market growth. The changes in the living style and value systems of people have affected the quality of birth. Additionally, the increasing use of preservatives and additives in children's diets raises the number of attention deficit hyperactivity disorder cases among the age group of 4-17 years. Therefore, this is fueling the growth of the global market.

This report includes the key players of the attention deficit hyperactivity market: Eli Lilly & Company, Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Hisamitsu Pharmaceutical Co., Inc Lupin Limited, NEOS Therapeutics Inc., Mallinckrodt Pharmaceuticals, and Impax Laboratories, LLC.

Henceforth, poor nutrition, infections, smoking, drinking, and substance abuse during pregnancy are the common reasons for the cause of attention deficit hyperactivity, where various therapeutics and drugs have a prominent role in the treatment. Moreover, this disorder is considered a social stigma since the emphasis on ADHD treatment has increased.

To provide an inclusive analysis on the attention deficit hyperactivity market by drug type, by age group, by distribution channel, and by region

To cater complete information on factors influencing market growth such as drivers, restraints, opportunities, and industry-specific restraints

To estimate the market size in key regions, which include North America, Europe, Asia Pacific, and the rest of the world

To register and evaluate competitive landscape mapping-product launches,

technological advancements, mergers, and expansions

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

2.1. Industry Overview

2.2. Industry Trends

3. MARKET SNAPSHOT

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. MARKET CHARACTERISTICS

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

5. DRUG TYPE: MARKET SIZE & ANALYSIS

5.1. Overview

5.2. Stimulant

5.3. Non-stimulant

6. DEMOGRAPHIC: MARKET SIZE & ANALYSIS

6.1. Overview

6.2. Adult (Aged 18 and above)

6.3. Children

7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS

Attention Deficit Hyperactivity Market by Drug Type (Stimulant and Non-stimulant), Demographic (Adult and Chil...

- 7.1. Overview
- 7.2. Retail Pharmacy
- 7.3. Hospital Pharmacy

8. GEOGRAPHY: MARKET SIZE & ANALYSIS

- 8.1. Overview
- 8.2. North America
- 8.3. Europe
- 8.4. Asia Pacific
- 8.5. Rest of the World

9. COMPETITIVE LANDSCAPE

- 9.1. Competitor Comparison Analysis
- 9.2. Market Developments
 - 9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
 - 9.2.2. Product Launches and execution

10. VENDOR PROFILES

- 10.1. Eli Lilly & Company
 - 10.1.1. Overview
 - 10.1.2. Financial Overview
 - 10.1.3. Product Offerings
 - 10.1.4. Developments
 - 10.1.5. Business Strategy
- 10.2. Johnson & Johnson Services Inc
 - 10.2.1. Overview
 - 10.2.2. Financial Overview
 - 10.2.3. Product Offerings
 - 10.2.4. Developments
 - 10.2.5. Business Strategy
- 10.3. Lupin Limited
 - 10.3.1. Overview
 - 10.3.2. Financial Overview
 - 10.3.3. Product Offerings
 - 10.3.4. Developments

- 10.3.5. Business Strategy
- 10.4. Mallinckrodt Pharmaceuticals
 - 10.4.1. Overview
 - 10.4.2. Financial Overview
 - 10.4.3. Product Offerings
 - 10.4.4. Developments
 - 10.4.5. Business Strategy
- 10.5. NEOS Therapeutics Inc.
 - 10.5.1. Overview
 - 10.5.2. Financial Overview
 - 10.5.3. Product Offerings
 - 10.5.4. Developments
 - 10.5.5. Business Strategy
- 10.6. Hisamitsu Pharmaceutical Co., Inc.
 - 10.6.1. Overview
 - 10.6.2. Financial Overview
 - 10.6.3. Product Offerings
 - 10.6.4. Developments
 - 10.6.5. Business Strategy
- 10.7. Impax Laboratories, LLC
 - 10.7.1. Overview
 - 10.7.2. Financial Overview
 - 10.7.3. Product Offerings
 - 10.7.4. Developments
 - 10.7.5. Business Strategy
- 10.8. Supernus Pharmaceuticals, Inc.
 - 10.8.1. Overview
 - 10.8.2. Financial Overview
 - 10.8.3. Product Offerings
 - 10.8.4. Developments
 - 10.8.5. Business Strategy
- 10.9. GlaxoSmithKline PLC
 - 10.9.1. Overview
 - 10.9.2. Financial Overview
 - 10.9.3. Product Offerings
 - 10.9.4. Developments
 - 10.9.5. Business Strategy
- 10.10. Purdue Pharma L.P.
 - 10.10.1. Overview

- 10.10.2. Financial Overview
- 10.10.3. Product Offerings
- 10.10.4. Developments
- 10.10.5. Business Strategy

11. ANALYST OPINION

12. ANNEXURE

- 12.1. Report Scope
- 12.2. Market Definitions
- 12.3. Research Methodology
 - 12.3.1. Data Collation and In-house Estimation
 - 12.3.2. Market Triangulation
 - 12.3.3. Forecasting
- 12.4. Report Assumptions
- 12.5. Declarations
- 12.6. Stakeholders
- 12.7. Abbreviations

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR STIMULANT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR NON-STIMULANT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR ADULT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR CHILDREN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 10. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 11. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 12. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 13. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 14. U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 15. U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 16. U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 17. CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 18. CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY

DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 19. CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 20. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 21. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 22. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 23. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 24. GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 25. GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 26. GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 27. U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 28. U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 29. U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 30. FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 31. FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 32. FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 33. ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 34. ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 35. ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 36. SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 37. SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 38. SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 39. ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 40. ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 41. ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 42. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 43. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 44. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 45. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 46. CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 47. CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 48. CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 49. INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 50. INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 51. INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 52. JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 53. JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 54. JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 55. REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 56. REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 57. REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET

VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 58. REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET
VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 59. REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET
VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

TABLE 60. REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET
VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

TABLE 61. ELI LILLY & COMPANY: FINANCIALS

TABLE 62. ELI LILLY & COMPANY: PRODUCTS & SERVICES

TABLE 63. ELI LILLY & COMPANY: RECENT DEVELOPMENTS

TABLE 64. JOHNSON & JOHNSON SERVICES INC: FINANCIALS

TABLE 65. JOHNSON & JOHNSON SERVICES INC: PRODUCTS & SERVICES

TABLE 66. JOHNSON & JOHNSON SERVICES INC: RECENT DEVELOPMENTS

TABLE 67. LUPIN LIMITED: FINANCIALS

TABLE 68. LUPIN LIMITED: PRODUCTS & SERVICES

TABLE 69. LUPIN LIMITED: RECENT DEVELOPMENTS

TABLE 70. MALLINCKRODT PHARMACEUTICALS: FINANCIALS

TABLE 71. MALLINCKRODT PHARMACEUTICALS: PRODUCTS & SERVICES

TABLE 72. MALLINCKRODT PHARMACEUTICALS: RECENT DEVELOPMENTS

TABLE 73. NEOS THERAPEUTICS INC.: FINANCIALS

TABLE 74. NEOS THERAPEUTICS INC.: PRODUCTS & SERVICES

TABLE 75. NEOS THERAPEUTICS INC.: RECENT DEVELOPMENTS

TABLE 76. HISAMITSU PHARMACEUTICAL CO., INC: FINANCIALS

TABLE 77. HISAMITSU PHARMACEUTICAL CO., INC: PRODUCTS & SERVICES

TABLE 78. HISAMITSU PHARMACEUTICAL CO., INC: RECENT DEVELOPMENTS

TABLE 79. IMPAX LABORATORIES, LLC: FINANCIALS

TABLE 80. IMPAX LABORATORIES, LLC: PRODUCTS & SERVICES

TABLE 81. IMPAX LABORATORIES, LLC: RECENT DEVELOPMENTS

TABLE 82. SUPERNUS PHARMACEUTICALS, INC: FINANCIALS

TABLE 83. SUPERNUS PHARMACEUTICALS, INC: PRODUCTS & SERVICES

TABLE 84. SUPERNUS PHARMACEUTICALS, INC: RECENT DEVELOPMENTS

TABLE 85. GLAXOSMITHKLINE PLC: FINANCIALS

TABLE 86. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES

TABLE 87. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

TABLE 88. PURDUE PHARMA L.P: FINANCIALS

TABLE 89. PURDUE PHARMA L.P: PRODUCTS & SERVICES

TABLE 90. PURDUE PHARMA L.P: RECENT DEVELOPMENTS

List Of Figures

LIST OF FIGURES

- CHART. 1. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
- CHART. 2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR STIMULANT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- CHART. 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR NON-STIMULANT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- CHART. 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- CHART. 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR ADULT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- CHART. 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR CHILDREN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- CHART. 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
- CHART. 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- CHART. 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- CHART. 10. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
- CHART. 11. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
- CHART. 12. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)
- CHART. 13. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
- CHART. 14. U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
- CHART. 15. U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)
- CHART. 16. U.S ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
- CHART. 17. CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
- CHART. 18. CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY

DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 19. CANADA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 20. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

CHART. 21. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 22. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 23. EUROPE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 24. GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 25. GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 26. GERMANY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 27. U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 28. U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 29. U.K ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 30. FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 31. FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 32. FRANCE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 33. ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 34. ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 35. ITALY ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 36. SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 37. SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 38. SPAIN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 39. ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 40. ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 41. ROE ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 42. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

CHART. 43. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 44. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 45. ASIA PACIFIC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 46. CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 47. CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 48. CHINA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 49. INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 50. INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 51. INDIA ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 52. JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 53. JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 54. JAPAN ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 55. REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 56. REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 57. REST OF APAC ATTENTION DEFICIT HYPERACTIVITY MARKET

VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

CHART. 58. REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET

VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

CHART. 59. REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET

VALUE, BY DEMOGRAPHIC, 2020-2026 (USD BILLION)

CHART. 60. REST OF WORLD ATTENTION DEFICIT HYPERACTIVITY MARKET

VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)

I would like to order

Product name: Attention Deficit Hyperactivity Market by Drug Type (Stimulant and Non-stimulant), Demographic (Adult and Children), Distribution Channel (Retail Pharmacy and Hospital Pharmacy), and Geography – Global Forecast up to 2026

Product link: <https://marketpublishers.com/r/ABC888B902BFEN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABC888B902BFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970